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Background/aim: This study aimed to assess expression changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patients
with entecavir treatment and explore the correlation with the curative effect.
Materials and methods: A total of 220 HBeAg-positive CHB patients and 207 healthy individuals were included. sPD-1 levels and
virological and biochemical responses were assessed at baseline and at 12, 24, and 48 weeks in CHB patients after antiviral therapy.
Results: sPD-1 levels in HBeAg-positive CHB patients before treatment were significantly lower than those of healthy controls. After
entecavir treatment, sPD-1 levels increased gradually over time. At 48 weeks after entecavir treatment, sPD-1 amounts in the HBeAg
seroconversion group were significantly higher than the values of the HBeAg-negative and HBeAg-positive groups. sPD-1 levels in
patients with alanine aminotransferase (ALT) returning to normal were significantly higher than in those with ALT not returning to
normal. sPD-1 levels in treated patients with no HBV-DNA were significantly higher than in those with HBV-DNA remaining positive.
sPD-1 was negatively correlated with ALT and HBV-DNA at 12, 24, and 48 weeks after entecavir treatment.
Conclusion: sPD-1 may play a certain role in chronic hepatitis B and has a close relationship with the curative effect of entecavir.
Key words: sPD-1, chronic hepatitis B, entecavir, curative effect

1. Introduction
Hepatitis B virus (HBV) belongs to Hepadnaviridae.
Persistent HBV infection remains a challenging global
health problem. After HBV intrusion into the adult body,
about 10% of infected individuals develop a chronic
infection called chronic hepatitis B (CHB) (1). Currently,
there are more than 370 million CHB patients, a number
projected to increase by 4 million per year. CHB is the
main factor responsible for cirrhosis and hepatocellular
carcinoma, and it accounts for approximately 1 million
deaths annually (2). Currently, immune tolerance is
considered the most important factor leading to CHB, but
its mechanism in the process of HBV infection remains
incompletely understood (3,4).
In CHB, persistent exposure to high concentrations of
viral antigens leads to various degrees of T-cell function
impairment, even T-cell exhaustion (5). Recent animal
models of chronic viral infection have indicated that
the interaction between programmed death-1 (PD-1), a
negative regulator of activated T-cells, and its ligand, PDL, plays a critical role in T-cell exhaustion (6,7). In addition
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to membrane-bound PD-1 on T cells, circulating soluble
PD-1 (sPD-1) has been described (8). Little is known about
the origin and physiological functions of sPD-1; however,
it has already been used as an antagonist of PD-1 signaling
in experimental studies (9). It was shown that sPD-1 blocks
the PD-1/PD-L pathway and is related to T-cell function
regulation in aplastic anemia (10). However, the biological
role of sPD-1 in CHB infection remains unknown.
In this study, changes of serum sPD-1 levels and
their correlation with the curative effect were assessed
in hepatitis B e antigen (HBeAg)-positive CHB patients
before and after treatment with entecavir; in addition, the
biological significance of sPD-1 in CHB was assessed.
2. Materials and methods
2.1. Study population
A total of 220 HBeAg-positive CHB patients and 207
healthy blood donors were included in this study. All
patients were treated at the Affiliated Hospital of Qingdao
University from February 2012 to May 2016. Diagnosis
was carried out according to criteria for viral hepatitis
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described by “The Guideline of Prevention and Treatment
for Chronic Hepatitis B” (2015 version) (11). Diagnostic
criteria for HBeAg-positive chronic hepatitis B were:
serum HBsAg- and HBeAg-positive, HBV-DNA-positive,
and ALT persistently or repeatedly increased or hepatitis
lesions in liver histological examination. The patients had
no obvious heart, brain, nerve, mental, or thyroid disease
and no diabetes or loss of compensated liver disease.
Patients with concomitant hepatitis virus and HIVinfection liver diseases were excluded. None of the patients
received antiviral or immunosuppressive therapy, or were
exposed to hepatotoxin. Subjects with other liver diseases
or liver cirrhosis were also excluded. There were 119 male
and 101 female patients aged 21–58 years, averaging 41 ±
15 years old.
Meanwhile, 207 healthy individuals were identified
from the physical examination center as the healthy control
group. They had no previous history or current evidence of
liver disease and had normal serum ALT levels. They were
also negative for HBsAg, anti-hepatitis A virus, anti-HCV,
and anti-HIV IgM antibodies. The controls included 107
male and 100 female healthy individuals aged 23–60 years,
averaging 40 ± 14 years old. Age and sex distribution were
not significantly different between the two groups (P >
0.05).
2.2. Antiviral therapy and follow-up
The patients received entecavir (0.5 mg/day). Virological
and biochemical response and immunological parameters
were assessed at baseline and at 12, 24, and 48 weeks during
the antiviral therapy. Each assessment included alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), total bilirubin (TBIL), HBV-DNA, HBeAg, and
sPD-1 detection. An adverse event inquiry was completed.
2.3. Ethics statement
The study protocol was approved by the ethics committee
of the Affiliated Hospital of Qingdao University. Each
patient provided a signed written informed consent form.
2.4. Reagents
The following reagents were used: sPD-1 ELISA Kit
(Shanghai Enzyme-Linked Biotechnology Co. Ltd.); HBV
Kit (Abbott Company); Hepatitis B Virus Nucleic Acid
Extraction and Purification Kit (Shanghai Renaissance
Long March Medical Science Co. Ltd.); ALT, AST, and
TBIL determination kits (North Controlled Biotech Corp).
2.5. Main outcome measures and methods
2.5.1. Detection of HBV markers
HBV markers included HBsAg, HBsAb, HBcAb, HBeAg,
and HBeAb. HBV markers were measured by the
chemiluminescence method (Anthos 2010, Austria),
according to the manufacturer’s instructions (SinoAmerican Biotech Co. Ltd, Shanghai, China). The samples
meeting the experimental requirements were screened

after test results were analyzed; the medical history of each
patient was then taken.
2.5.2. Serum sPD-1 content measurement
The levels of serum sPD-1 were assessed with the ELISA
kit described above, strictly in accordance with the
manufacturer’s instructions.
2.5.3. Liver function test
The detection of liver enzymes, including serum ALT,
AST, and TBIL, was carried out using routine automated
techniques (upper limit of normal levels: 50 U/L, 40 U/L,
and 17.1 µmol/mL, respectively) (HITACHI 7600.210,
Japan).
2.5.4. Detection of HBV-DNA levels
Serum HBV viral load was quantitated by real-time
quantitative PCR, strictly in accordance with the
manufacturer’s instructions. The primers were: HBV
forward 5’-GAC CAC CAA ATG CCC CTA T-3’; HBV
508 reverse, 5’-AAG CGC TGC GTG TAG TTT CT-3’.
The probes were: HBV FL, 5’-GAV GCA GGW CCC CTA
GAA AAA AAA-fluorescein-3’; HBV LC, 5’-LVRde-TCC
CTC GCC TCG CAG ACG AAG TRC TS-phosphate-3’.
The sensitivity of this test was 102 IU/mL. Values below the
detection limit were assumed to be 102 IU/mL.
2.6. Statistical analysis
All statistical analyses were carried out with SPSS 20.0
software. Data are mean ± standard deviation (SD).
Analysis of variance and t-test were performed for
comparison between groups. Correlation analyses between
sPD-1, ALT, and HBV-DNA were assessed by Pearson
correlation analysis. P < 0.05 was considered statistically
significant.
3. Results
3.1. Clinical outcomes
The serological characteristics of the 220 HBeAg-positive
CHB patients before entecavir treatment and at 12, 24, and
48 weeks of entecavir treatment, as well as those of healthy
controls, are shown in Table 1.
3.2. Changes of sPD-1, ALT, and HBV-DNA
The expression levels of sPD-1 in HBeAg-positive CHB
patients before treatment were significantly lower than
those of healthy controls (t = 22.792, P = 0.000). With
time after entecavir treatment, sPD-1 increased gradually;
values before treatment and at 12, 24, and 48 weeks after
treatment were significantly different (F = 199.849, P =
0.000). Indeed, sPD-1 levels at 12, 24, and 48 weeks were
significantly higher than baseline values (t = –2.951,
–11.739, –22.238; P = 0.003, 0.000, 0.000, respectively).
However, sPD-1 levels at 48 weeks after treatment remained
lower than control values, with a statistically significant
difference (t = 3.867, P = 0.000). With increasing treatment
time, ALT and HBV-DNA levels decreased gradually and
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were statistically significant (F = 309.495, 4260.24; P =
0.000, 0.000, respectively). Specifically, ALT and HBVDNA amounts in patients at 48 weeks were significantly
lower than baseline levels (t = 18.671, 113.41; P = 0.000,
0.000, respectively); however, ALT at 48 weeks remained
significantly higher compared with control values (t =
–12.182, P = 0.000).
3.3. Correlation between sPD-1 levels and HBeAg, ALT,
and HBV-DNA
3.3.1. Correlation between sPD-1 levels and HBeAg
At 48 weeks after entecavir treatment, the 220 CHB
patients were divided into 3 groups according to HBeAg
levels: HBeAg seroconversion, HBeAg-negative (HBeAgnegative and no seroconversion), and HBeAg-positive.
As shown in Table 2, sPD-1 expression levels in the 3
groups at 48 weeks were significantly higher than baseline
amounts (t = 16.883, 7.948, 266.784; P = 0.000, 0.000,
0.000, respectively). There were no statistically significant
differences in sPD-1 amounts among the 3 groups before
treatment (F = 0.055, P = 0.9470). However, the 3 groups
showed significantly different values at 48 weeks after
treatment (F = 22.034, P = 0.000). Precisely, sPD-1 levels
in the HBeAg seroconversion group were significantly
higher than those of HBeAg-negative and HBeAg-positive
groups (t = 2.378, 7.005; P = 0.020, 0.000, respectively).
Meanwhile, sPD-1 amounts in the HBeAg-negative group

were significantly higher than the values obtained for
patients with continuously positive HBeAg (t = 2.013, P
= 0.046).
3.3.2. Correlation between sPD-1 levels and ALT
At 48 weeks after entecavir treatment, ALT returned to
normal in 180 cases and remained higher in 40 patients.
The expression levels of sPD-1 in the two patient groups at
48 weeks were significantly higher than baseline amounts
(t = 21.223, 7.711; P = 0.000, 0.000, respectively). There
was no difference in sPD-1 levels between the two groups
before treatment (t = 0.671, P = 0.503). Interestingly, sPD1 levels in patients with ALT that had returned to normal
levels were significantly higher than those obtained from
patients with continuously higher ALT (t = 2.866, P =
0.004) (Table 3).
3.3.3. Correlation between sPD-1 levels and HBV-DNA
At 48 weeks after antiviral therapy, HBV-DNA was not
detected in 204 cases and remained positive in 16 cases.
The expression levels of sPD-1 in the two groups at 48
weeks were significantly higher than baseline values (t =
21.892, 4.673; P = 0.000, 0.000, respectively). There was no
difference in sPD-1 amounts between the two groups before
treatment (t = 0.441, P = 0.660). However, sPD-1 levels in
patients with no HBV-DNA detection were significantly
higher than those obtained for patients retaining positive
HBV-DNA (t = 2.159, P = 0.032) (Table 4).

Table 1. Serological characteristics of HBeAg-positive chronic hepatitis B patients
(before and after entecavir treatment) and healthy controls (mean ± SD).
Groups

ALT
(U/L)

HBV-DNA
(Ig IU/mL)

sPD-1
(ng/L)

Healthy controls

21.6 ± 4.6

Negative

51.18 ± 10.58

Baseline

268.4 ± 184.7

7.70 ± 0.62

32.01 ± 6.05

12 weeks

55.5 ± 32.8*

3.02 ± 0.65*

33.86 ± 7.12*

24 weeks

41.9 ± 22.8*

2.46 ± 0.55*

39.69 ± 7.60*

48 weeks

35.1 ± 15.7*

2.25 ± 0.41*

47.58 ± 8.44*

*Significant change compared with baseline, P < 0.05.
Table 2. Expression levels of sPD-1 in CHB patients with different HBeAg outcomes (mean ± SD).
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Groups

Cases

sPD-1 before
treatment (ng/L)

sPD-1 at
48 weeks (ng/L)

t

P

HBeAg seroconversion

54

32.07 ± 6.10

53.35 ± 6.97

16.883

0.000

HBeAg-negative

21

31.59 ± 6.53

48.98 ± 7.60

7.948

0.000

HBeAg-positive

145

266.784

0.000

32.04 ± 6.00

45.23 ± 8.01

F

0.055

22.034

P

0.947

0.000
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Table 3. Expression levels of sPD-1 in CHB patients with different ALT outcomes (mean ± SD).
Groups

Cases

sPD-1 before
treatment (ng/L)

sPD-1 at
48 weeks (ng/L)

t

P

ALT returned to normal

180

32.13 ± 6.113

48.34 ± 8.21

21.223

0.000

ALT not returned to normal

40

7.711

0.000

31.42 ± 5.72

44.15 ± 8.72

t

0.671

2.866

P

0.503

0.004

Table 4. Expression levels of sPD-1 in CHB patients with different HBV-DNA outcomes (mean ± SD).
Groups

Cases

sPD-1 before
treatment (ng/L)

HBV-DNA-negative after treatment

204

32.06 ± 6.12

HBV-DNA-positive after treatment

16

31.36 ± 5.23

sPD-1 at
48 weeks (ng/L)

t

P

47.92 ± 8.35

21.892

0.000

43.27 ± 8.71

4.673

0.000

T

0.441

2.159

P

0.660

0.032

3.4. Correlation analysis of sPD-1, ALT, and HBV-DNA
in patients with HBV
Before entecavir treatment in CHB patients, sPD-1 and
the clinical biochemical indicators ALT and HBV-DNA
were not related. sPD-1 showed negative correlations with
ALT (r = –0.366, P = 0.000; Figure 1) and HBV-DNA (r =
–0.393, P = 0.000; Figure 2) at 12, 24, and 48 weeks after
entecavir treatment in CHB patients. Their regression
equations are Y = –0.134X + 46.288 and Y = –5.926X +
55.661, respectively.
3.5. Adverse reactions
Creatine kinase amounts were increased slightly in 4 cases
during entecavir treatment and relieved after rest, without
discontinuation of entecavir treatment. Other individuals
showed no overt adverse reactions.
4. Discussion
The pathogenesis of CHB is complex, and the host immune
response cannot effectively eliminate the hepatitis B
virus. Recent evidence has suggested that T cells play an
important role in CHB patients, with decreased cellular
immune function (12). There are various degrees of T-cell
function impairment, even T-cell exhaustion, in chronic
HBV infection (5). PD-1 is an inhibitory receptor on
the surface of activated T cells (13). The combination
of PD-1 with PD-L1 is an immune suppression signal.
This inhibitory signal can negatively regulate activation,
proliferation, and cytokine production in T cells when
delivered to them. This signal transduction pathway is
considered to be related to the chronic infection of CHB
(14). Studies have shown that PD-1 and PD-L1 counts in

peripheral blood mononuclear cells of CHB patients are
increased (15,16).
An increasing number of studies demonstrate
that many costimulatory molecules exist in both cell
membrane and soluble forms, e.g., CD40, 4-1BBL, OX40L,
CD86, CD80, and CTLA-4. sPD-1 is the soluble form of
PD-1, with extracellular domains like IgV structures on
the cell surface portion of PD-1 (8). Molecules on the cell
membrane mediate costimulatory signals through direct
receptor–ligand interactions; on the other hand, soluble
protein factors play important regulatory roles in the
immune response, like the function of cytokines. Not only
do they affect near-end cells, but they also bind receptors
on the far-end cell surface. These features make them
participate in occurrence and development of diseases,
with a far more important role than body membrane
surface molecules.
Studies have demonstrated that sPD-1 has a role in
blocking the PD-1/PD-L pathway in immune-related
diseases. Recently, it was found that sPD-1 has a strong
ability to bind PD-ligand, since it has a PD-1 extracellular
domain. This can compete with PD-1 and restore the
killing and secretion functions of T-cells (17,18). Wu et
al. assessed the abnormal activation of T cells in patients
with aplastic anemia and demonstrated that sPD-1
can block membrane PD-1 in T cells, which results in
abnormal proliferation and activation of T cells (10). Wan
et al. found abnormally high expression of sPD-1 in the
peripheral blood and synovial fluid of rheumatoid arthritis
patients, with sPD-1 expression level closely related to
the body concentration of rheumatoid factor (19). Other
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Figure 1. Correlation between sPD-1 and ALT at 12, 24, and 48 weeks after entecavir
treatment in CHB patients.

Figure 2. Correlation between sPD-1 and HBV-DNA at 12, 24, and 48 weeks after entecavir
treatment in CHB patients.
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studies also indicated that sPD-1 has a role in blocking the
PD-1/PD-L pathway in hepatocellular carcinoma. He et
al. deemed that sPD-1 could block the PD-1/PD-L1 (B7.
H1) pathway to improve tumor escape in a mouse model
of liver cancer (20). Wang et al. (21) showed that sPD-1
is associated with pathological injury in chronic HCV
infection.
However, the biological role of sPD-1 in hepatitis B
virus infection remains unknown. Immune factors also
play an important role, and the PD-1/PD-L1 pathway
increases in CHB. Since sPD-1 could block the PD-1/
PD-L1 pathway, it might play an important role in the
development of CHB. As shown above, serum sPD-1
levels in HBeAg-positive chronic hepatitis B patients were
reduced, indicating that sPD-1 may play a certain role in
the development and progression of chronic hepatitis B. In
CHB patients, sPD-1 levels were decreased, thus increasing
PD-1 activity and potentially decreasing T-cell function.
Entecavir is one of the most effective anti-HBV drugs
used extensively worldwide. It inhibits viral replication
by substituting a similar nucleoside, which is required in
the HBV replication process, therefore terminating chain
elongation. Meanwhile, studies have shown that entecavir
plays a role in regulating the immune system. You et
al. demonstrated the restoration of the T-lymphocyte
subpopulation in CHB patients treated with entecavir (22).
However, changes of serum sPD-1 levels in CHB before
and after treatment with entecavir are poorly understood,
as well as the relationships of sPD-1 with ALT, HBeAg, and
HBV-DNA.
We evaluated HBeAg-positive CHB patients before
and after treatment with entecavir for 48 weeks. As shown
above, sPD-1 levels increased gradually with treatment
time. This indicated that entecavir antiviral might increase
sPD-1 expression and restore T-cell function. Meanwhile,

the expression of sPD-1 remained lower than baseline
at 48 weeks after treatment, which may be related to the
incomplete recovery of the CHB patients at 48 weeks after
entecavir treatment. Interestingly, sPD-1 levels in the
HBeAg seroconversion group were significantly higher
than those of the HBeAg-negative and HBeAg-positive
groups at 48 weeks, suggesting that sPD-1 is basically
associated with HBeAg prognosis. These findings indicated
that sPD-1 could be used as a valid predictive factor for
HBeAg in the late stage of seroconversion. The expression
levels of sPD-1 in patients with ALT returned to normal
were significantly higher than those in patients with ALT
remaining abnormal; meanwhile, sPD-1 amounts in
patients with no HBV-DNA were significantly elevated
compared with values obtained for patients still HBVDNA-positive. These findings indicate that sPD-1 has a
close relationship with the curative effect of entecavir. In
this study, sPD-1 was negatively correlated with ALT and
HBV-DNA at 12, 24, and 48 weeks of entecavir treatment
in CHB patients. This suggests that sPD-1 levels can be
used for disease assessment; furthermore, a given drug
regimen can be stopped quickly when a bad therapeutic
effect appears, which would save money and time.
In summary, this study suggests that sPD-1, as a marker
of T-cell function, may play a certain role in CHB and has
a close relationship with the curative effect of entecavir
treatment in CHB patients. These findings provide new
insights for understanding the pathogenesis and treatment
of HBV.
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